The liposomal drug delivery devices market size has grown rapidly in recent years. It will grow from $5.34 billion in 2025 to $6.01 billion in 2026 at a compound annual growth rate (CAGR) of 12.4%. The growth in the historic period can be attributed to advancements in nanotechnology-based drug delivery, increasing cancer prevalence, expansion of injectable drug formulations, rising use of liposomal antifungal therapies, growing pharmaceutical research investments.
The liposomal drug delivery devices market size is expected to see rapid growth in the next few years. It will grow to $9.49 billion in 2030 at a compound annual growth rate (CAGR) of 12.1%. The growth in the forecast period can be attributed to increasing demand for targeted cancer treatments, expansion of personalized medicine approaches, growing adoption of advanced drug delivery platforms, rising investments in biologics and vaccines, increasing focus on reducing drug toxicity. Major trends in the forecast period include increasing adoption of targeted drug delivery systems, rising use of pegylated liposomal formulations, growing application in oncology therapies, expansion of liposomal vaccines and antifungals, enhanced focus on controlled drug release.
The increasing number of cancer cases worldwide is expected to drive the growth of the liposomal drug delivery devices market in the coming years. Cancer encompasses a wide range of diseases marked by the uncontrolled growth and spread of abnormal cells; the rising incidence is influenced by population aging, environmental risk factors, and lifestyle changes. As cancer prevalence increases, there is a growing need for advanced, targeted therapies such as liposomal formulations, which can enhance drug delivery, minimize systemic toxicity, and improve treatment outcomes. For example, in February 2024, the World Health Organization, a Switzerland-based intergovernmental organization, reported that approximately 20 million new cancer cases were recorded in 2022, with projections indicating an increase to 35 million by 2050, representing a 77% rise. Consequently, the escalating global cancer burden is fueling the expansion of the liposomal drug delivery devices market.
Major companies in the liposomal drug delivery devices market are launching innovative products such as hydrochloride liposome injections to strengthen their market position. Researchers are focused on creating liposomal nanostructures that enhance patient adherence by enabling less frequent dosing while ensuring therapeutic effectiveness. For example, in August 2024, Lupin Ltd., an India-based pharmaceutical company, introduced Doxorubicin Hydrochloride Liposome Injection in 20 mg/10 mL (2 mg/mL) and 50 mg/25 mL (2 mg/mL) formulations. The Doxorubicin Hydrochloride Liposome Injection generated estimated annual sales of around USD 40.9 million in the U.S. market as of June 2024. This launch strategically positions Lupin within the oncology segment as it broadens its portfolio to include this critical cancer treatment. Lupin’s dedication to enhancing patient health outcomes is reflected in this introduction, as the company seeks to offer effective treatment options in a competitive pharmaceutical environment.
In October 2024, Liquidia Corporation, a US-based provider of biopharmaceutical therapies for rare cardiopulmonary diseases, broadened its partnership with Pharmosa Biopharm to further the development of L606. Through this expanded collaboration, Liquidia aims to enhance its capabilities in liposomal drug delivery by incorporating Pharmosa’s proprietary liposomal formulation and inhalation device technologies to jointly develop L606, a sustained-release inhaled treprostinil therapy. Pharmosa Biopharm is a Taiwan-based biotechnology company dedicated to creating innovative drugs using advanced liposomal drug delivery systems and inhalation platforms.
Major companies operating in the liposomal drug delivery devices market are Pfizer Inc., Johnson & Johnson Services Inc., Merck & Co. Inc., Novartis AG, Gilead Sciences Inc., Ipsen SA, Shanghai Fudan Zhangjiang Bio-Pharmaceutical Co. Ltd., Nanomerics Ltd., Luye Pharma Group Ltd., Leadiant Biosciences Inc., Pacira Biosciences Inc., Nippon Kayaku Co. Ltd., Celsion Corporation, Acrotech Biopharma Inc., Aphios Pharma LLC, CytImmune Sciences Inc., NanoSphere Health Sciences Inc., Cel-Sci Corporation, Lipoid GmbH, Liposome Company Inc., Liposome Research Days Corporation, Taiwan Liposome Company.
North America was the largest region in the liposomal drug delivery devices market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the liposomal drug delivery devices market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the liposomal drug delivery devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the liposomal drug delivery devices market by increasing costs of imported pharmaceutical-grade lipids, encapsulation equipment, precision manufacturing systems, and quality testing instruments. Pharmaceutical manufacturers in North America and Europe are most affected due to reliance on specialized imported inputs, while Asia-Pacific faces cost pressure on formulation manufacturing. These tariffs are increasing production costs and extending development timelines. However, they are also encouraging local sourcing of raw materials, regional manufacturing expansion, and innovation in scalable liposomal production technologies.
The liposomal drug delivery devices market research report is one of a series of new reports that provides liposomal drug delivery devices market statistics, including liposomal drug delivery devices industry global market size, regional shares, competitors with a liposomal drug delivery devices market share, detailed liposomal drug delivery devices market segments, market trends and opportunities, and any further data you may need to thrive in the liposomal drug delivery devices industry. This liposomal drug delivery devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Liposomal drug delivery devices are microscopic colloidal spheres utilized to transport drug molecules to specific action sites.
Primary types encompass liposomal doxorubicin, liposomal paclitaxel, liposomal amphotericin B, and others. Liposomal doxorubicin, a chemotherapy drug under the anthracycline category, encapsulated within a liposome, inhibits cancer cell growth by blocking the enzyme topoisomerase. These devices find applications in treating fungal diseases, cancer therapy, pain management, viral vaccines, and photodynamic therapy, utilized in hospitals, diagnostic centers, ambulatory surgery centers/clinics, and similar medical settings.
The liposomal drug delivery devices market consists of sales of instruments such as liposomal doxorubicin, liposomal paclitaxel, liposomal amphotericin B, and others. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The liposomal drug delivery devices market size is expected to see rapid growth in the next few years. It will grow to $9.49 billion in 2030 at a compound annual growth rate (CAGR) of 12.1%. The growth in the forecast period can be attributed to increasing demand for targeted cancer treatments, expansion of personalized medicine approaches, growing adoption of advanced drug delivery platforms, rising investments in biologics and vaccines, increasing focus on reducing drug toxicity. Major trends in the forecast period include increasing adoption of targeted drug delivery systems, rising use of pegylated liposomal formulations, growing application in oncology therapies, expansion of liposomal vaccines and antifungals, enhanced focus on controlled drug release.
The increasing number of cancer cases worldwide is expected to drive the growth of the liposomal drug delivery devices market in the coming years. Cancer encompasses a wide range of diseases marked by the uncontrolled growth and spread of abnormal cells; the rising incidence is influenced by population aging, environmental risk factors, and lifestyle changes. As cancer prevalence increases, there is a growing need for advanced, targeted therapies such as liposomal formulations, which can enhance drug delivery, minimize systemic toxicity, and improve treatment outcomes. For example, in February 2024, the World Health Organization, a Switzerland-based intergovernmental organization, reported that approximately 20 million new cancer cases were recorded in 2022, with projections indicating an increase to 35 million by 2050, representing a 77% rise. Consequently, the escalating global cancer burden is fueling the expansion of the liposomal drug delivery devices market.
Major companies in the liposomal drug delivery devices market are launching innovative products such as hydrochloride liposome injections to strengthen their market position. Researchers are focused on creating liposomal nanostructures that enhance patient adherence by enabling less frequent dosing while ensuring therapeutic effectiveness. For example, in August 2024, Lupin Ltd., an India-based pharmaceutical company, introduced Doxorubicin Hydrochloride Liposome Injection in 20 mg/10 mL (2 mg/mL) and 50 mg/25 mL (2 mg/mL) formulations. The Doxorubicin Hydrochloride Liposome Injection generated estimated annual sales of around USD 40.9 million in the U.S. market as of June 2024. This launch strategically positions Lupin within the oncology segment as it broadens its portfolio to include this critical cancer treatment. Lupin’s dedication to enhancing patient health outcomes is reflected in this introduction, as the company seeks to offer effective treatment options in a competitive pharmaceutical environment.
In October 2024, Liquidia Corporation, a US-based provider of biopharmaceutical therapies for rare cardiopulmonary diseases, broadened its partnership with Pharmosa Biopharm to further the development of L606. Through this expanded collaboration, Liquidia aims to enhance its capabilities in liposomal drug delivery by incorporating Pharmosa’s proprietary liposomal formulation and inhalation device technologies to jointly develop L606, a sustained-release inhaled treprostinil therapy. Pharmosa Biopharm is a Taiwan-based biotechnology company dedicated to creating innovative drugs using advanced liposomal drug delivery systems and inhalation platforms.
Major companies operating in the liposomal drug delivery devices market are Pfizer Inc., Johnson & Johnson Services Inc., Merck & Co. Inc., Novartis AG, Gilead Sciences Inc., Ipsen SA, Shanghai Fudan Zhangjiang Bio-Pharmaceutical Co. Ltd., Nanomerics Ltd., Luye Pharma Group Ltd., Leadiant Biosciences Inc., Pacira Biosciences Inc., Nippon Kayaku Co. Ltd., Celsion Corporation, Acrotech Biopharma Inc., Aphios Pharma LLC, CytImmune Sciences Inc., NanoSphere Health Sciences Inc., Cel-Sci Corporation, Lipoid GmbH, Liposome Company Inc., Liposome Research Days Corporation, Taiwan Liposome Company.
North America was the largest region in the liposomal drug delivery devices market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the liposomal drug delivery devices market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the liposomal drug delivery devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the liposomal drug delivery devices market by increasing costs of imported pharmaceutical-grade lipids, encapsulation equipment, precision manufacturing systems, and quality testing instruments. Pharmaceutical manufacturers in North America and Europe are most affected due to reliance on specialized imported inputs, while Asia-Pacific faces cost pressure on formulation manufacturing. These tariffs are increasing production costs and extending development timelines. However, they are also encouraging local sourcing of raw materials, regional manufacturing expansion, and innovation in scalable liposomal production technologies.
The liposomal drug delivery devices market research report is one of a series of new reports that provides liposomal drug delivery devices market statistics, including liposomal drug delivery devices industry global market size, regional shares, competitors with a liposomal drug delivery devices market share, detailed liposomal drug delivery devices market segments, market trends and opportunities, and any further data you may need to thrive in the liposomal drug delivery devices industry. This liposomal drug delivery devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Liposomal drug delivery devices are microscopic colloidal spheres utilized to transport drug molecules to specific action sites.
Primary types encompass liposomal doxorubicin, liposomal paclitaxel, liposomal amphotericin B, and others. Liposomal doxorubicin, a chemotherapy drug under the anthracycline category, encapsulated within a liposome, inhibits cancer cell growth by blocking the enzyme topoisomerase. These devices find applications in treating fungal diseases, cancer therapy, pain management, viral vaccines, and photodynamic therapy, utilized in hospitals, diagnostic centers, ambulatory surgery centers/clinics, and similar medical settings.
The liposomal drug delivery devices market consists of sales of instruments such as liposomal doxorubicin, liposomal paclitaxel, liposomal amphotericin B, and others. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Liposomal Drug Delivery Devices Market Characteristics
3. Liposomal Drug Delivery Devices Market Supply Chain Analysis
4. Global Liposomal Drug Delivery Devices Market Trends and Strategies
5. Liposomal Drug Delivery Devices Market Analysis of End Use Industries
7. Global Liposomal Drug Delivery Devices Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Liposomal Drug Delivery Devices Total Addressable Market (TAM) Analysis for the Market
9. Liposomal Drug Delivery Devices Market Segmentation
10. Liposomal Drug Delivery Devices Market Regional and Country Analysis
11. Asia-Pacific Liposomal Drug Delivery Devices Market
12. China Liposomal Drug Delivery Devices Market
13. India Liposomal Drug Delivery Devices Market
14. Japan Liposomal Drug Delivery Devices Market
15. Australia Liposomal Drug Delivery Devices Market
16. Indonesia Liposomal Drug Delivery Devices Market
17. South Korea Liposomal Drug Delivery Devices Market
18. Taiwan Liposomal Drug Delivery Devices Market
19. South East Asia Liposomal Drug Delivery Devices Market
20. Western Europe Liposomal Drug Delivery Devices Market
21. UK Liposomal Drug Delivery Devices Market
22. Germany Liposomal Drug Delivery Devices Market
23. France Liposomal Drug Delivery Devices Market
24. Italy Liposomal Drug Delivery Devices Market
25. Spain Liposomal Drug Delivery Devices Market
26. Eastern Europe Liposomal Drug Delivery Devices Market
27. Russia Liposomal Drug Delivery Devices Market
28. North America Liposomal Drug Delivery Devices Market
29. USA Liposomal Drug Delivery Devices Market
30. Canada Liposomal Drug Delivery Devices Market
31. South America Liposomal Drug Delivery Devices Market
32. Brazil Liposomal Drug Delivery Devices Market
33. Middle East Liposomal Drug Delivery Devices Market
34. Africa Liposomal Drug Delivery Devices Market
36. Liposomal Drug Delivery Devices Market Competitive Landscape and Company Profiles
37. Liposomal Drug Delivery Devices Market Other Major and Innovative Companies
40. Liposomal Drug Delivery Devices Market High Potential Countries, Segments and Strategies
41. Appendix
List of Tables
Executive Summary
Liposomal Drug Delivery Devices Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses liposomal drug delivery devices market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for liposomal drug delivery devices? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The liposomal drug delivery devices market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Type: Liposomal Doxorubicin; Liposomal Paclitaxel; Liposomal Amphotericin B; Other Types2) By Application: Fungal Diseases; Cancer Therapy; Pain Management; Viral Vaccines; Photodynamic Therapy
3) By End User: Hospitals; Diagnostic Centers; Ambulatory Surgery Centers/Clinics; Other End Users
Subsegments:
1) By Liposomal Doxorubicin: Conventional Liposomal Doxorubicin; PEGylated Liposomal Doxorubicin2) By Liposomal Paclitaxel: Conventional Liposomal Paclitaxel; PEGylated Liposomal Paclitaxel
3) By Liposomal Amphotericin B: Conventional Liposomal Amphotericin B; PEGylated Liposomal Amphotericin B
4) By Other Types: Liposomal Irinotecan; Liposomal Vincristine; Liposomal Cytarabine
Companies Mentioned: Pfizer Inc.; Johnson & Johnson Services Inc.; Merck & Co. Inc.; Novartis AG; Gilead Sciences Inc.; Ipsen SA; Shanghai Fudan Zhangjiang Bio-Pharmaceutical Co. Ltd.; Nanomerics Ltd.; Luye Pharma Group Ltd.; Leadiant Biosciences Inc.; Pacira Biosciences Inc.; Nippon Kayaku Co. Ltd.; Celsion Corporation; Acrotech Biopharma Inc.; Aphios Pharma LLC; CytImmune Sciences Inc.; NanoSphere Health Sciences Inc.; Cel-Sci Corporation; Lipoid GmbH; Liposome Company Inc.; Liposome Research Days Corporation; Taiwan Liposome Company
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Liposomal Drug Delivery Devices market report include:- Pfizer Inc.
- Johnson & Johnson Services Inc.
- Merck & Co. Inc.
- Novartis AG
- Gilead Sciences Inc.
- Ipsen SA
- Shanghai Fudan Zhangjiang Bio-Pharmaceutical Co. Ltd.
- Nanomerics Ltd.
- Luye Pharma Group Ltd.
- Leadiant Biosciences Inc.
- Pacira Biosciences Inc.
- Nippon Kayaku Co. Ltd.
- Celsion Corporation
- Acrotech Biopharma Inc.
- Aphios Pharma LLC
- CytImmune Sciences Inc.
- NanoSphere Health Sciences Inc.
- Cel-Sci Corporation
- Lipoid GmbH
- Liposome Company Inc.
- Liposome Research Days Corporation
- Taiwan Liposome Company
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 6.01 Billion |
| Forecasted Market Value ( USD | $ 9.49 Billion |
| Compound Annual Growth Rate | 12.1% |
| Regions Covered | Global |
| No. of Companies Mentioned | 23 |
